Replies to post #690377 on NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

What most don’t appreciate here is that before the NHS signs a Provision of Goods or Services contract with a third party supplier , that company is audited separately, and outside of the Regulatory Framework, by looking at ALL information available about it from conception.

This is just a part of the NHS’s normal safe-guarding due-diligence.

[skitahoe]

We definitely have different beliefs, I think NICE will consider the use of Poly-ICLC with DCVax-L and therefore see a far greater percentage of patients seeing a major improvement. Furthermore by the end of this year, or early next at the latest, I believe the EDEN will be accepted by the regulators for production.

When you look only at 5 year data you're not seeing substantial benefits to those who don't live 5 years. I've known a few pancreatic cancer patients who very much enjoyed most of the 2 to 3 years they were given with treatment, it probably would have been well under a year without it. While I've not known GBM patients, I believe much the same applies to GBM.

Of course when you add Poly-ICLC 50% are living to, or beyond 5 years. I suspect that many who don't live 5 years will be living to near that point, but more data is really needed. Frankly I think that the crew at UCLA in a larger trial may actually be able to take 5 year survival to closer to 60% or even 70%. Frankly the more they learn about treatment with the vaccine and other therapeutics the greater percentage that will live and the longer they'll live.

Gary

[Nemesis18]

8 out of a 100 vs. 13 out of a 100. NICE will see right through that. Even if they believe it they'll say $300,000 a piece for 87 out of 100 who won't see any real benefit. Perhaps they'll allow for some small identifiable subset but that won't help shareholders.

This is 100% correct. IMO

[drugrunner]

It’s 13% versus 5% LC it’s amazing how your number keeps growing with every lie you tell